Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study.
Identifieur interne : 000330 ( Main/Exploration ); précédent : 000329; suivant : 000331Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study.
Auteurs : S. Jiménez-Jorge [Espagne] ; C. Savulescu ; F. Pozo ; S. De Mateo ; I. Casas ; J. Ledesma ; A. LarrauriSource :
- Vaccine [ 1873-2518 ] ; 2012.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Espagne (épidémiologie), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (épidémiologie), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Nourrisson (MeSH), Nouveau-né (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Études cas-témoins (MeSH).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine.
- épidémiologie : Espagne, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Enfant d'âge préscolaire, Femelle, Humains, Jeune adulte, Mâle, Nourrisson, Nouveau-né, Sujet âgé, Sujet âgé de 80 ans ou plus, Études cas-témoins.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Case-Control Studies (MeSH), Child (MeSH), Child, Preschool (MeSH), Female (MeSH), Humans (MeSH), Infant (MeSH), Infant, Newborn (MeSH), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Male (MeSH), Middle Aged (MeSH), Spain (epidemiology), Young Adult (MeSH).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , immunology : Influenza Vaccines.
- geographic , epidemiology : Spain.
- epidemiology : Influenza, Human.
- prevention & control : Influenza, Human.
- Adolescent, Adult, Aged, Aged, 80 and over, Case-Control Studies, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Young Adult.
Abstract
BACKGROUND
In Spain, the influenza vaccine effectiveness (VE) was estimated in the last three seasons using an observational study (cycEVA) conducted in the frame of the Spanish Influenza Sentinel Surveillance System. We aimed to measure the effectiveness of the seasonal trivalent vaccine in preventing influenza like illness (ILI) laboratory-confirmed influenza infection at the end of the season 2010-11.
METHODS
We conducted a test-negative case-control study between weeks 50/2010 and 12/2011. Cases were ILI laboratory-confirmed influenza infection and controls were those testing negative. Sentinel physicians collected data on demographic and clinical characteristics, vaccination status, and on covariates related to confounding factors associating with influenza VE. We calculated adjusted odds ratios (OR), using logistic regression and computed influenza VE as (1-OR) × 100.
RESULTS
The adjusted influenza VE against A(H1N1)pdm09 infection was 46% (95% confidence interval (95%CI): 0; 72). In A(H1N1)pdm09 infected patients who had received both 2010-11 trivalent influenza seasonal and 2009 monovalent pandemic vaccines, influenza VE was 74% (95%CI: 13; 93). The adjusted influenza VE against B infection was 23% (95%CI: -180; 79).
CONCLUSION
The trivalent influenza vaccine 2010-11 showed a moderate VE for preventing ILI laboratory confirmed influenza infections. Influenza VE estimates were higher in patients who had received both 2010-11 seasonal trivalent and 2009 monovalent pandemic vaccines.
DOI: 10.1016/j.vaccine.2012.03.048
PubMed: 22472792
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study.</title><author><name sortKey="Jimenez Jorge, S" sort="Jimenez Jorge, S" uniqKey="Jimenez Jorge S" first="S" last="Jiménez-Jorge">S. Jiménez-Jorge</name><affiliation wicri:level="2"><nlm:affiliation>Institute of Health Carlos III, National Centre of Epidemiology, c/Monforte de Lemos no. 5, 28029 Madrid, Spain. sjimenezj@isciii.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institute of Health Carlos III, National Centre of Epidemiology, c/Monforte de Lemos no. 5, 28029 Madrid</wicri:regionArea><placeName><region nuts="2" type="communauté">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Savulescu, C" sort="Savulescu, C" uniqKey="Savulescu C" first="C" last="Savulescu">C. Savulescu</name></author><author><name sortKey="Pozo, F" sort="Pozo, F" uniqKey="Pozo F" first="F" last="Pozo">F. Pozo</name></author><author><name sortKey="De Mateo, S" sort="De Mateo, S" uniqKey="De Mateo S" first="S" last="De Mateo">S. De Mateo</name></author><author><name sortKey="Casas, I" sort="Casas, I" uniqKey="Casas I" first="I" last="Casas">I. Casas</name></author><author><name sortKey="Ledesma, J" sort="Ledesma, J" uniqKey="Ledesma J" first="J" last="Ledesma">J. Ledesma</name></author><author><name sortKey="Larrauri, A" sort="Larrauri, A" uniqKey="Larrauri A" first="A" last="Larrauri">A. Larrauri</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22472792</idno><idno type="pmid">22472792</idno><idno type="doi">10.1016/j.vaccine.2012.03.048</idno><idno type="wicri:Area/Main/Corpus">00303</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00303</idno><idno type="wicri:Area/Main/Curation">000303</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000303</idno><idno type="wicri:Area/Main/Exploration">000303</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study.</title><author><name sortKey="Jimenez Jorge, S" sort="Jimenez Jorge, S" uniqKey="Jimenez Jorge S" first="S" last="Jiménez-Jorge">S. Jiménez-Jorge</name><affiliation wicri:level="2"><nlm:affiliation>Institute of Health Carlos III, National Centre of Epidemiology, c/Monforte de Lemos no. 5, 28029 Madrid, Spain. sjimenezj@isciii.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Institute of Health Carlos III, National Centre of Epidemiology, c/Monforte de Lemos no. 5, 28029 Madrid</wicri:regionArea><placeName><region nuts="2" type="communauté">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Savulescu, C" sort="Savulescu, C" uniqKey="Savulescu C" first="C" last="Savulescu">C. Savulescu</name></author><author><name sortKey="Pozo, F" sort="Pozo, F" uniqKey="Pozo F" first="F" last="Pozo">F. Pozo</name></author><author><name sortKey="De Mateo, S" sort="De Mateo, S" uniqKey="De Mateo S" first="S" last="De Mateo">S. De Mateo</name></author><author><name sortKey="Casas, I" sort="Casas, I" uniqKey="Casas I" first="I" last="Casas">I. Casas</name></author><author><name sortKey="Ledesma, J" sort="Ledesma, J" uniqKey="Ledesma J" first="J" last="Ledesma">J. Ledesma</name></author><author><name sortKey="Larrauri, A" sort="Larrauri, A" uniqKey="Larrauri A" first="A" last="Larrauri">A. Larrauri</name></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Case-Control Studies (MeSH)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Infant (MeSH)</term><term>Infant, Newborn (MeSH)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Spain (epidemiology)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Espagne (épidémiologie)</term><term>Femelle (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Nourrisson (MeSH)</term><term>Nouveau-né (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term><term>Études cas-témoins (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Infant</term><term>Infant, Newborn</term><term>Male</term><term>Middle Aged</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Nourrisson</term><term>Nouveau-né</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études cas-témoins</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>In Spain, the influenza vaccine effectiveness (VE) was estimated in the last three seasons using an observational study (cycEVA) conducted in the frame of the Spanish Influenza Sentinel Surveillance System. We aimed to measure the effectiveness of the seasonal trivalent vaccine in preventing influenza like illness (ILI) laboratory-confirmed influenza infection at the end of the season 2010-11.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We conducted a test-negative case-control study between weeks 50/2010 and 12/2011. Cases were ILI laboratory-confirmed influenza infection and controls were those testing negative. Sentinel physicians collected data on demographic and clinical characteristics, vaccination status, and on covariates related to confounding factors associating with influenza VE. We calculated adjusted odds ratios (OR), using logistic regression and computed influenza VE as (1-OR) × 100.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The adjusted influenza VE against A(H1N1)pdm09 infection was 46% (95% confidence interval (95%CI): 0; 72). In A(H1N1)pdm09 infected patients who had received both 2010-11 trivalent influenza seasonal and 2009 monovalent pandemic vaccines, influenza VE was 74% (95%CI: 13; 93). The adjusted influenza VE against B infection was 23% (95%CI: -180; 79).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>The trivalent influenza vaccine 2010-11 showed a moderate VE for preventing ILI laboratory confirmed influenza infections. Influenza VE estimates were higher in patients who had received both 2010-11 seasonal trivalent and 2009 monovalent pandemic vaccines.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22472792</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2012</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>24</Issue><PubDate><Year>2012</Year><Month>May</Month><Day>21</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study.</ArticleTitle><Pagination><MedlinePgn>3595-602</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2012.03.048</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In Spain, the influenza vaccine effectiveness (VE) was estimated in the last three seasons using an observational study (cycEVA) conducted in the frame of the Spanish Influenza Sentinel Surveillance System. We aimed to measure the effectiveness of the seasonal trivalent vaccine in preventing influenza like illness (ILI) laboratory-confirmed influenza infection at the end of the season 2010-11.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a test-negative case-control study between weeks 50/2010 and 12/2011. Cases were ILI laboratory-confirmed influenza infection and controls were those testing negative. Sentinel physicians collected data on demographic and clinical characteristics, vaccination status, and on covariates related to confounding factors associating with influenza VE. We calculated adjusted odds ratios (OR), using logistic regression and computed influenza VE as (1-OR) × 100.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The adjusted influenza VE against A(H1N1)pdm09 infection was 46% (95% confidence interval (95%CI): 0; 72). In A(H1N1)pdm09 infected patients who had received both 2010-11 trivalent influenza seasonal and 2009 monovalent pandemic vaccines, influenza VE was 74% (95%CI: 13; 93). The adjusted influenza VE against B infection was 23% (95%CI: -180; 79).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The trivalent influenza vaccine 2010-11 showed a moderate VE for preventing ILI laboratory confirmed influenza infections. Influenza VE estimates were higher in patients who had received both 2010-11 seasonal trivalent and 2009 monovalent pandemic vaccines.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiménez-Jorge</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Health Carlos III, National Centre of Epidemiology, c/Monforte de Lemos no. 5, 28029 Madrid, Spain. sjimenezj@isciii.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savulescu</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pozo</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>de Mateo</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Casas</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Ledesma</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Larrauri</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><CollectiveName>cycEVA Study Team</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Spanish Influenza Sentinel Surveillance System</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Giménez</LastName><ForeName>Jaume</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanrell</LastName><ForeName>Juana M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Carolina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vega</LastName><ForeName>Tomás</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martínez</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torner</LastName><ForeName>Nuria</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramos</LastName><ForeName>Julián M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Serrano</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castilla</LastName><ForeName>Jesús</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>García Cenoz</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Altzíbar</LastName><ForeName>Jone M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arteagoitia</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiñones</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perucha</LastName><ForeName>Milagros</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castrillejo</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>03</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>03</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22472792</ArticleId><ArticleId IdType="pii">S0264-410X(12)00440-9</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2012.03.048</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Communauté de Madrid</li></region></list><tree><noCountry><name sortKey="Casas, I" sort="Casas, I" uniqKey="Casas I" first="I" last="Casas">I. Casas</name><name sortKey="De Mateo, S" sort="De Mateo, S" uniqKey="De Mateo S" first="S" last="De Mateo">S. De Mateo</name><name sortKey="Larrauri, A" sort="Larrauri, A" uniqKey="Larrauri A" first="A" last="Larrauri">A. Larrauri</name><name sortKey="Ledesma, J" sort="Ledesma, J" uniqKey="Ledesma J" first="J" last="Ledesma">J. Ledesma</name><name sortKey="Pozo, F" sort="Pozo, F" uniqKey="Pozo F" first="F" last="Pozo">F. Pozo</name><name sortKey="Savulescu, C" sort="Savulescu, C" uniqKey="Savulescu C" first="C" last="Savulescu">C. Savulescu</name></noCountry><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Jimenez Jorge, S" sort="Jimenez Jorge, S" uniqKey="Jimenez Jorge S" first="S" last="Jiménez-Jorge">S. Jiménez-Jorge</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000330 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000330 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22472792
|texte= Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22472792" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |